Image source: Shutterstock

Highlights

  • NEU recorded AUD 213.2 million in revenue and AUD 166.2 million in comprehensive income in FY24.
  • The company is progressing NNZ-2591 in clinical trials for rare neurodevelopmental disorders, with new trials targeting HIE in newborns and a Phase 3 trial in Phelan-McDermid syndrome set for mid-2025.
  • NEU intends to expand its global market reach into Europe, Canada, and Japan.

Neuren Pharmaceuticals Limited (ASX:NEU) is an ASX-listed biopharmaceutical company, focusing on the development and commercialisation of novel treatments for neurological disorders. The company is making significant progress with its lead products, DAYBUE™ (trofinetide) and NNZ-2591.

In its financial year 2024 (FY24), NEU reported total revenue of AUD 213.2 million from customer contracts and AUD 11 million in interest income, with total comprehensive income rising 6% YoY to AUD 166.2 million. A key contributor in revenue was USD 56 million in royalties from DAYBUE™ sales in the US, reflecting a 110% YoY increase. Additionally, milestone income of AUD 80.5 million was earned in FY24, driven by the commercial performance of DAYBUE™. A reduction in income tax expense further bolstered profitability.

Market potential of NEU Products

DAYBUE™ achieved USD 348 million in global sales in its first full year and more than 60% of patients remained on therapy beyond 12 months. The company is targeting further expansion through launches in Europe, Canada, and Japan, anticipating increased regulatory approvals and royalty inflows.

Meanwhile, NNZ-2591 is advancing through clinical development for multiple rare neurological conditions, including Phelan-McDermid syndrome, Pitt Hopkins syndrome, and Angelman syndrome. In March 2025, NEU announced the initiation of NNZ-2591 for treating hypoxic-ischemic encephalopathy (HIE) in newborns, with plans for FDA pre-IND meetings and clinical trials in Q4 2025. A Phase 3 trial for Phelan-McDermid syndrome is also scheduled to begin by mid-2025.

Recent business developments

Through an ASX update dated 7 April 2025, the company announced ashare buyback program, repurchasing over 2.4 million securities for a total of AUD 29.55 million.

Outlook

Looking ahead, NEU expects continued revenue growth on the back of the expanding royalties from DAYBUETM sales and commercialisation. The royalties and global sales of DAYBUETM are anticipated to increase substantially through expected regulatory approvals in new markets including Europe and Japan.

To summarise, the company aims to sustain revenue growth by deepening its global market presence, securing new regulatory approvals, and leveraging strategic collaborations with partners such as Acadia.

Share performance of NEU

NEU shares closed 6.14% lower at AUD 8.72 per share on 8 April 2025. Over the past year, NEU’s share price has declined by approximately 57.44%, including a 6-month drop of 33.84%. The stock’s 52-week high stands at AUD 24.00, recorded on 27 May 2024, while its 52-week low of AUD 8.61 was reached recently on 7 April 2025.

Support and Resistance Summary

Note 1: Past performance is neither an Indicator nor a guarantee of future performance.

Note 2: The reference date for all price data, and currency, is 09 April 2025. The reference data in this report has been partly sourced from EODHD/Others.

 

Technical Indicators Defined:

Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock.

Resistance: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Resistance 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Resistance 2 may act as the crucial resistance level for the stock.